ES2199592T3 - Procedimiento para secar hidrocloruro de paroxetina anhidro. - Google Patents
Procedimiento para secar hidrocloruro de paroxetina anhidro.Info
- Publication number
- ES2199592T3 ES2199592T3 ES99945685T ES99945685T ES2199592T3 ES 2199592 T3 ES2199592 T3 ES 2199592T3 ES 99945685 T ES99945685 T ES 99945685T ES 99945685 T ES99945685 T ES 99945685T ES 2199592 T3 ES2199592 T3 ES 2199592T3
- Authority
- ES
- Spain
- Prior art keywords
- isopropyl alcohol
- anhydrous
- paroxetine
- hydrochloride
- drying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title claims abstract description 185
- 238000001035 drying Methods 0.000 title claims abstract description 60
- 229960002296 paroxetine Drugs 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title claims abstract description 40
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title claims abstract description 36
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 title claims description 38
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 245
- 229960005183 paroxetine hydrochloride Drugs 0.000 claims abstract description 71
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims abstract description 8
- 229960000656 paroxetine hydrochloride anhydrous Drugs 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 3
- -1 paroxetine compound Chemical class 0.000 abstract description 8
- 239000013078 crystal Substances 0.000 description 48
- 238000002360 preparation method Methods 0.000 description 17
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 239000001569 carbon dioxide Substances 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 238000002056 X-ray absorption spectroscopy Methods 0.000 description 1
- 238000000441 X-ray spectroscopy Methods 0.000 description 1
- QUWBSOKSBWAQER-UHFFFAOYSA-N [C].O=C=O Chemical compound [C].O=C=O QUWBSOKSBWAQER-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10105898A JP3796351B2 (ja) | 1998-04-13 | 1998-04-13 | パロキセチン塩酸塩無水和物の乾燥方法 |
| JP10105898 | 1998-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2199592T3 true ES2199592T3 (es) | 2004-02-16 |
Family
ID=14290525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99945685T Expired - Lifetime ES2199592T3 (es) | 1998-04-13 | 1999-04-12 | Procedimiento para secar hidrocloruro de paroxetina anhidro. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6541637B1 (enExample) |
| EP (1) | EP0990655B1 (enExample) |
| JP (1) | JP3796351B2 (enExample) |
| AT (1) | ATE244237T1 (enExample) |
| AU (1) | AU730652B2 (enExample) |
| CA (1) | CA2294716C (enExample) |
| DE (1) | DE69909207T2 (enExample) |
| ES (1) | ES2199592T3 (enExample) |
| PT (1) | PT990655E (enExample) |
| WO (1) | WO1999052902A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1394160A1 (en) | 1996-06-13 | 2004-03-03 | SUMIKA FINE CHEMICALS Co., Ltd. | Process for preparing crystalline paroxetin hydrochloride |
| DK1100796T3 (da) * | 1998-08-07 | 2003-08-25 | Smithkline Beecham Plc | Fremgangsmåde til fremstilling af en ikke-krystallinsk anhydratform af paroxetinhydrochlorid |
| GB9826176D0 (en) * | 1998-11-28 | 1999-01-20 | Smithkline Beecham Plc | Novel process |
| US20080033050A1 (en) * | 2006-08-04 | 2008-02-07 | Richards Patricia Allison Tewe | Method of treating thermoregulatory disfunction with paroxetine |
| US9138430B2 (en) * | 2007-12-27 | 2015-09-22 | Mylan Specialty L.P. | Formulation and method for the release of paroxetine in the large intestine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK283608B6 (sk) | 1995-02-06 | 2003-10-07 | Smithkline Beecham Plc | Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie |
| US5856493A (en) * | 1995-02-06 | 1999-01-05 | Smithkline Beecham Corporation | Process for making novel form of paroxeting hydrochloride anhydrate |
| EP1394160A1 (en) * | 1996-06-13 | 2004-03-03 | SUMIKA FINE CHEMICALS Co., Ltd. | Process for preparing crystalline paroxetin hydrochloride |
| JP3819532B2 (ja) | 1996-06-13 | 2006-09-13 | 住友化学株式会社 | ピペリジン誘導体およびその製造方法 |
| DK1100796T3 (da) * | 1998-08-07 | 2003-08-25 | Smithkline Beecham Plc | Fremgangsmåde til fremstilling af en ikke-krystallinsk anhydratform af paroxetinhydrochlorid |
-
1998
- 1998-04-13 JP JP10105898A patent/JP3796351B2/ja not_active Expired - Fee Related
-
1999
- 1999-04-12 ES ES99945685T patent/ES2199592T3/es not_active Expired - Lifetime
- 1999-04-12 DE DE69909207T patent/DE69909207T2/de not_active Expired - Lifetime
- 1999-04-12 CA CA002294716A patent/CA2294716C/en not_active Expired - Fee Related
- 1999-04-12 AU AU52656/99A patent/AU730652B2/en not_active Ceased
- 1999-04-12 PT PT99945685T patent/PT990655E/pt unknown
- 1999-04-12 WO PCT/JP1999/001914 patent/WO1999052902A1/ja not_active Ceased
- 1999-04-12 EP EP99945685A patent/EP0990655B1/en not_active Expired - Lifetime
- 1999-04-12 AT AT99945685T patent/ATE244237T1/de active
- 1999-04-12 US US09/445,598 patent/US6541637B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0990655A1 (en) | 2000-04-05 |
| JP2001072677A (ja) | 2001-03-21 |
| EP0990655A4 (en) | 2001-10-04 |
| PT990655E (pt) | 2003-11-28 |
| CA2294716A1 (en) | 1999-10-21 |
| ATE244237T1 (de) | 2003-07-15 |
| AU730652B2 (en) | 2001-03-08 |
| DE69909207D1 (de) | 2003-08-07 |
| JP3796351B2 (ja) | 2006-07-12 |
| CA2294716C (en) | 2004-08-03 |
| DE69909207T2 (de) | 2004-04-22 |
| EP0990655B1 (en) | 2003-07-02 |
| AU5265699A (en) | 1999-11-01 |
| WO1999052902A1 (en) | 1999-10-21 |
| US6541637B1 (en) | 2003-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2346782T3 (es) | Monohidrato de azitromicina. | |
| ES2336287T5 (es) | Modificaciones polimórficas de ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazolcarboxílico y procedimientos para su preparación | |
| NO328465B1 (no) | Krystallinsk monohydrat, fremgangsmate for fremstilling derav og anvendelse derav til fremstilling av et medikament | |
| JP2718637B2 (ja) | ガランタミン誘導体、それらの製法および医薬としてのそれらの使用 | |
| ES2199592T3 (es) | Procedimiento para secar hidrocloruro de paroxetina anhidro. | |
| ES2477290T3 (es) | Método mejorado para preparar meropenem usando polvo de zinc | |
| EP1652848A1 (en) | Process for producing imide compound | |
| ES2259725T3 (es) | Nuevas formas cristalinas del meloxicam y procedimientos para su preparacion e interconversion. | |
| KR101102288B1 (ko) | (3ｓ,5ｓ)-7-(3-아미노-5-메틸-피페리디닐)-1-사이클로프로필-1,4-다이하이드로-8-메톡시-4-옥소-3-퀴놀린카르복실산의 말레이트 염 및 다형체 | |
| CA2513951A1 (en) | Method for the production of d-threo-2-phenyl-2-piperidine-2-yl acetate | |
| ES2288984T3 (es) | Procedimiento para producir un cristal polimorfico de hidrocloruro de donepezilo. | |
| US20080103298A1 (en) | Process for the preparation of sucralose by the chlorination of sugar with triphosgene (btc) | |
| ES2394688T3 (es) | Fase precursora y su utilización para preparar la sal de magnesio tetrahidratada de un enantiómero del omeprazol | |
| ES2386165T3 (es) | Procedimiento para la producción de mirtazapina | |
| NO316987B1 (no) | Fremgangsmate for fremstilling av 4,10-diacetoksy-2<alfa>-benzoyloksy-5<beta>,20-epoksy-1,7<beta>-dihydroksy-9-okso-tax-11-en-13<alfa>-YL (2R,3S)-3-benzoylamino-2-hydroksy-3-fenylpropionat-trihydrat og den oppnadde forbindelse | |
| ES2294333T3 (es) | Procedimiento para la eliminacion de la impureza s de la forma polimorfica i de la olanzapina. | |
| JP4130078B2 (ja) | カルバペネム誘導体結晶と注射製剤 | |
| WO2002092605A1 (en) | CRYSTAL OF HYDRATE OF ß-LACTAM COMPOUND | |
| ES2373341T3 (es) | Procedimiento para la preparación de pleuromutilinas. | |
| ES2338871T3 (es) | Proceso para la preparacion de cristales de zonisamida sin 1,2-dicloroetano y cristales de zonisamida muy puros. | |
| NO148887B (no) | Fremgangsmaate til fremstilling av det krystallinske anhydrat av natriumcefamandol | |
| ES2314583T4 (es) | Proceso para sintesis de los derivados del acido (2s,3as,7as)-1-(s)-alanil-octahidro-1h-indol-2-carboxilico y su utilizacion en la sintesis de perindropil. | |
| JPS61165390A (ja) | 結晶質アミノメチル化合物 | |
| EP1726591A2 (en) | Process for manufacturing paroxetine hydrochloride hemihydrate | |
| ES2272198B1 (es) | Procedimiento para la obtencion de hidrato de calcipotriol. |